NEW YORK, April 23, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Continuous Glucose Monitoring Market (CGM Systems, Application, Diabetic Type, and Adoption by Age Group) - Current Trends, Size, Share, Industry Analysis, Competitive Intelligence, Growth, Opportunities and Global Forecasts, 2012 - 2020

http://www.reportlinker.com/p02014011/Continuous-Glucose-Monitoring-Market-CGM-Systems-Application-Diabetic-Type-and-Adoption-by-Age-Group---Current-Trends-Size-Share-Industry-Analysis-Competitive-Intelligence-Growth-Opportunities-and-Global-Forecasts-2012---2020.html

Rise in incidence of diabetes across the globe has elevated the need of innovative diabetic management devices that has increased adoption of continuous glucose monitoring (CGM) devices. The existing glucose monitoring devices have few gaps which are bridged by the innovative CGM. With continuous glucose monitoring, significant improvement has been observed in stabilizing elevated A1C levels which in turn reduces risk of developing long term diabetic complications. Other driving factors for CGM market are technological innovation in the form of artificial pancreas, increasing awareness among developed, developing and under developed economies, and rise in incidences of diabetic cases. However, factors such as strict regulatory impositions, inadequate reimbursement options for CGM and accuracy as well as cost of the CGMs are restraining the market growth.The global continuous glucose monitors market generated revenue of $194.8 million in 2012 and is expected to reach market size of value $568.5 million by 2020, growing at a CAGR of 14.8% during 2013-2020. This growth is attributed to increase in technological innovations, namely launch of artificial pancreas, convenience offered by CGM over self monitoring glucose devices, and earlier detection of the hypo & hyperglycemic events by CGM.

Global CGM market is segmented based on application as home settings, diagnostics and hospitals. Among all the application segments home settings is expected to generate maximum revenue by 2020.

North America is the maximum revenue-generating segment across the globe, mainly due to rapid acceptance of innovative technology, well-penetrated reimbursement system when compared with other geographies and rise in patient pool. Asia Pacific is expected to grow at a faster rate due to large patient pool, geographical expansion of market players, increase in income levels and improved living standards of the people.

Key market players in this market includes, Medtronics, Dexcom, Animas Corporation, Ypsomed AG, Omnipod and Miraculins, Inc inlcuding others. The major strategy adopted the market players across this geography is Collaborations, Product launches and approvals. Collaborations specifically focus on distribution and commercialization of the devices.

KEY BENEFITS

The report ranks the factors that are responsible to accelerate the market growth driven by upper hand of CGM over Self monitoring glucose devices, approval for artificial pancreas and many more
Market is forecasted for period of seven years 2013 to 2020 with market revenues for 2 historic years of 20110and 2012
Identification and analysis of key pockets of investment for CGM manufacturers
Identification of challenges that must be addressed and overcome in the CGM market to achieve fiscal success throughout the market
Analysis of regulatory framework that regulates introduction of new CGM and puts light on reimbursement scenario
The report identifies and profiles key market participants that would drive innovation in the CGM market

KEY MARKET SEGMENTS

GLOBAL MARKET, BY DEVICES

Transmitter and Receivers
Sensors
Insulin Pump

GLOBAL MARKET, BY APPLICATION

Diagnostics/Clinics
Hospitals
Home Settings

GLOBAL MARKET, BY AGE

Children and Teens
Youth
Middle, Elderly and Aged

GLOBAL MARKET, BY GEOGRAPHY

North America
Europe
Asia Pacific
Row

KEY AUDIENCES

Medical Devices Manufacturers
Research Institutions
Healthcare Institutions

Table of Contents

CHAPTER 1 INTRODUCTION
1.1 Objectives and Scope
1.2 Report Description
1.3 Key Benefits of the Report
1.4 Research Methodology
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 GLOBAL CONTINUOUS GLUCOSE MONITORS MARKET OVERVIEW
3.1 Healthcare Expenditure on Diabetes Worldwide
3.2 Type-1 Diabetics to Remain Key Target for CGM Market
3.2.1 Type-1 Diabetes
3.2.1.1 Type-1 Diabetes in Young People
3.2.2 Type-2 Diabetes
3.2.2.1 Type-2 Diabetes in Young People
3.2.3 Gestational Diabetes
3.2.4 Other Types of Diabetes
3.3 Market Intelligence
3.3.1 Top Factors Impacting Continuous Glucose Monitors Market, 2013-2020
3.3.1.1 Fda Approval of Artificial Pancreas
3.3.1.2 Convenience Offered by CGM Over Self Monitoring Glucose Devices
3.3.1.3 Rise in Incidences of Diabetes Cases Globally
3.3.1.4 Earlier Detection of the Hypo and Hyperglycemic Events by CGM
3.3.1.5 Inadequate Reimbursement Options for CGM Serve as Barriers for its Adoption
3.3.1.6 Accuracy and Cost Acts as a Hindrance in Continuing Use of CGM
3.3.1.7 Strict Regulatory Impositions
3.3.1.8 Increase in Awareness Among Developing and Underdeveloped Economies
3.3.2 Top Three Winning Strategies in the Continuous Glucose Monitors Market
3.3.2.1 Global Market Players Positioning
3.3.3 Top Investment Pockets in Continuous Glucose Monitors Market
3.3.3.1 Continuous Glucose Monitors Market – by Device
3.3.3.2 Continuous Glucose Monitors Market – by Applications
3.3.3.3 Continuous Glucose Monitors Market – by Geography
3.4 Regulations
3.5 Reimbursement Scenario
3.6 Market Dynamics
3.6.1 Drivers
3.6.1.1 Convenience Offered by CGM Over Self Monitoring Glucose Devices
3.6.1.2 FDA Approval of Artificial Pancreas Enables Closing the Loop and Overcomes the Limitation of Current Diabetes Care Management System
3.6.1.3 Earlier Detection of the Hypo and Hyperglycemic Events by CGM
3.6.1.4 Rise in Incidences of Diabetes Cases Globally
3.6.1.5 Increase in Awareness Among the Population in Developing and Underdeveloped Economies
3.6.2 Restraints
3.6.2.1 Strict Regulatory Impositions
3.6.2.2 Inadequate Reimbursement Options for CGM Serve as Barriers for its Adoption
3.6.2.3 Accuracy and Cost Acts as a Hindrance in Continuing Use of CGM
3.6.3 Market Opportunity
3.6.3.1 Growth in Emerging Market
3.6.4 Winning Strategies for Mncs in Emerging Markets
3.6.4.1 Tailoring the Existing Products to the Local Market Needs
3.6.4.2 Adoption of a Proactive Hybrid Model Rather Than Distributor Management
3.6.4.3 Service Rendered Makes a Difference
3.6.4.4 Partnership and Acquisition Key to Enhance Reach and Market Position
3.6.4.5 Adopting An Emerging-Market Attitude
CHAPTER 4 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET - BY DEVICES
4.1 Transmitter and Receivers
4.2 Sensors
4.2.1 Market Trend
4.2.1.1 Non-Invasive Glucose Sensors
4.2.1.2 Subcutaneous Sensors (Minimally Invasive Sensors)
4.2.1.3 Conventional Technology – Holter-Type Retrospective Sensors
4.2.1.4 Advanced Technology – Real-Time Sensors
4.3 Insulin Pump
4.3.1 Advantages of Insulin Pump
4.3.2 Disadvantages of Insulin Pump
4.3.3 Market Trend
CHAPTER 5 CONTINUOUS GLUCOSE MONITORING SYSTEM MARKET - BY APPLICATION
5.1 Diagnostics/Clinics
5.2 Hospitals
5.3 Home Settings
5.4 Role of CGM in Private Practice
5.4.1 Team Members
5.4.2 Clinical Space
5.4.3 Scheduling
5.4.4 Keeping the Patients Informed
CHAPTER 6 CONTINUOUS GLUCOSE MONITORING SYSTEM MARKET – BY AGE
6.1 Children and Teens
6.2 Youth
6.3 Middle Elderly and Aged
CHAPTER 7 CGM SYSTEMS MARKET BY GEOGRAPHY
7.1 North America
7.2 Europe
7.2.1 Financial Cost Incurred
7.3 Asia Pacific
7.4 Row
CHAPTER 8 COMPANY PROFILES
8.1 Medtronic Inc.
8.1.1 Company Overview
8.1.2 Company Snapshot
8.1.3 Business Performance
8.1.4 Strategic Moves and Developments
8.1.4.1 Principal Strategies: Product Launch
8.1.4.2 Secondary Strategies: Approval
8.1.4.3 Other Strategies: Collaboration
8.1.5 SWOT Analysis & Strategic Conclusions
8.2 Dexcom Inc.
8.2.1 Company Overview
8.2.2 Company Snapshot
8.2.3 Business Performance
8.2.4 Strategic Moves and Developments
8.2.4.1 Principal Strategies: Agreement/Partnership
8.2.4.2 Secondary Strategies: Acquisition
8.2.5 SWOT Analysis & Strategic Conclusions
8.3 Novo Nordisk
8.3.1 Company Profile
8.3.2 Company Snapshot
8.3.3 Strategic Moves and Developments
8.3.4 SWOT Analysis & Strategic Conclusions
8.4 Spring Health Solution Ltd
8.4.1 Company Profile
8.4.2 Company Snapshot
8.4.3 Strategic Moves and Developments
8.4.3.1 Principal Strategies
8.4.4 SWOT Analysis & Strategic Conclusions
8.5 Roche
8.5.1 Company Profile
8.5.2 Company Snapshot
8.5.3 Strategic Moves and Developments
8.5.4 SWOT Analysis & Strategic Conclusions
8.6 Animas Corporation
8.6.1 Company Profile
8.6.2 Company Snapshot
8.6.3 Strategic Moves and Developments
8.6.3.1 Principal Strategies
8.6.4 SWOT Analysis & Strategic Conclusions
8.7 Ypsomed AG
8.7.1 Company Profile
8.7.2 Company Snapshot
8.7.3 Strategic Moves and Developments
8.7.3.1 Principal Strategies: Product Expansion
8.7.3.2 Secondary Strategies: New Subsidiary
8.7.3.3 Other Strategies: Acquisition and Agreements
8.7.4 SWOT Analysis & Strategic Conclusions
8.8 Insulet Corporation
8.8.1 Company Profile
8.8.2 Company Snapshot
8.8.3 Strategic Moves and Developments
8.8.3.1 Principal Strategies
8.8.4 SWOT Analysis & Strategic Conclusions



List of Tables

TABLE 1 FEATURES OF CURRENTLY AVAILABLE STAND-ALONE CGM SYSTEMS (AS OF MARCH 2013)
TABLE 2 FEATURES OF CURRENTLY AVAILABLE INTEGRATED CGM SYSTEMS (AS OF MARCH 2013)
TABLE 3 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET BY PRODUCT CATEGORY, 2011-2020, ($MILLION)
TABLE 4 GLOBAL CGM TRANSMITTERS AND RECEIVERS MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 5 GLOBAL CGM SENSORS MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 6 GLOBAL CGM INSULIN PUMP MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 7 GLOBAL CGM MARKET BY APPLICATION SEGMENTS, 2011 - 2020, ($MILLION)
TABLE 8 GLOBAL CGM MARKET IN DIAGNOSTIC CENTERS, BY GEOGRAPHY, 2011 - 2020, ($THOUSAND)
TABLE 9 GLOBAL CGM MARKET IN HOSPITALS, BY GEOGRAPHY, 2011 - 2020, ($THOUSAND)
TABLE 10 GLOBAL CGM MARKET IN HOME SETTINGS, BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 11 GLOBAL CGM MARKET BY AGE, 2011 - 2020, ($MILLION)
TABLE 12 TYPE-1 DIABETES (0-14 YEARS), 2013
TABLE 13 FACTORS IMPACTING GEOGRAPHICAL REGIONS IN 2013 AND 2020
TABLE 14 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 15 THE PREVALENCE OF DIABETES IN THE ADULT POPULATION ACROSS THE U.K. IN 2011
TABLE 16 PREVALENCE ESTIMATES OF DIABETES (20-79 YEARS), 2013, EUROPE
TABLE 17 PREVALENCE ESTIMATES OF DIABETES, 2013 & 2035
TABLE 18 PREVALENCE ESTIMATES OF DIABETES (20-79 YEARS), 2013, AFRICA REGION
TABLE 19 MEDTRONIC BUSINESS SNAPSHOT
TABLE 20 DEXCOM INC. BUSINESS SNAPSHOT
TABLE 21 NOVA NORDISK BUSINESS SNAPSHOT
TABLE 22 SPRING HEALTH SOLUTION LTD BUSINESS SNAPSHOT
TABLE 23 ROCHE BUSINESS SNAPSHOT
TABLE 24 ANIMAS CORPORATION BUSINESS SNAPSHOT
TABLE 25 YPSOMED AG BUSINESS SNAPSHOT
TABLE 26 INSULET CORPORATION BUSINESS SNAPSHOT



List of Figures

FIG. 1 GLOBAL HEALTH EXPENDITURE DUE TO DIABETES, BY GEOGRAPHY ($BILLION)
FIG. 2 GLOBAL HEALTH EXPENDITURE DUE TO DIABETES, 20-79 YEARS ($BILLION)
FIG. 3 TREATMENT OF DIABETES, 2011
FIG. 4 SIMILARITIES IN CAUSE OF PRE-DIABETES AND TYPE-2 DIABETES
FIG. 5 CGM ADOPTION BY DIFFERENT TYPES OF DIABETES PATIENTS
FIG. 6 PREVALENCE OF TYPE-1 DIABETES, BY GEOGRAPHY, (THOUSAND)
FIG. 7 GLOBAL PREVALENCE OF TYPE-2 DIABETES IN 2000 & ESTIMATED PREVALENCE IN 2030
FIG. 8 TOP FACTORS IMPACTING CGM MARKET, 2013-2020
FIG. 9 TOP WINNING STRATEGY IN CGM MARKET, 2010 TO 2013 (SEPTEMBER)
FIG. 10 TOP WINNING STRATEGY IN CGM MARKET BY YEAR
FIG. 11 GLOBAL MARKET PLAYERS POSITIONING
FIG. 12 TOP INVESTMENT POCKETS IN CGM DEVICE MARKETS
FIG. 13 TOP INVESTMENT POCKETS IN CGM APPLICATION MARKETS
FIG. 14 TOP INVESTMENT POCKETS IN CGM GEOGRAPHY MARKETS
FIG. 15 NUMBER OF INCIDENCES OF DIABETES GLOBALLY, BY GEOGRAPHY (2000, 2011 & 2030)
FIG. 16 GDP PER CAPITA IN EMERGING ECONOMIES
FIG. 17 EMERGING MARKET CAPITALIZATION STRATEGIES
FIG. 18 GLOBAL CGM MARKET AMONG CHILDREN, 2011-2020, ($MILLION)
FIG. 19 GLOBAL CGM MARKET AMONG TEENS, 2011-2020, ($MILLION)
FIG. 20 GLOBAL CGM MARKET AMONG YOUTH, 2011-2020, ($MILLION)
FIG. 21 GLOBAL CGM MARKET AMONG MIDDLE ELDERLY, 2011-2020, ($MILLION)
FIG. 22 GLOBAL CGM MARKET AMONG AGED, 2011-2020, ($MILLION)
FIG. 23 NORTH AMERICA CGM MARKET, 2013-2020, ($MILLION)
FIG. 24 CASES OF DIABETES BY AGES IN NAC (1000S) (2013 E)
FIG. 25 EUROPE CGM MARKET, 2013-2020, ($MILLION)
FIG. 26 CASES OF DIABETES BY AGES IN EUROPE (1000S) (2013 E)
FIG. 27 ASIA PACIFIC CGM MARKET, 2013-2020, ($MILLION)
FIG. 28 TOP 10 COUNTRIES WITH DIABETES INCIDENCES 2013 AND 2035
FIG. 29 ROW CGM MARKET, 2013-2020, ($MILLION)
FIG. 30 FINANCIAL REVENUES BY BUSINESS UNITS (2013)
FIG. 31 FINANCIAL REVENUES BY GEOGRAPHY (2013)
FIG. 32 FINANCIAL REVENUES BY GEOGRAPHY (2012)





Companies Covered

Medtronic Inc., Dexcom Inc., Novo Nordisk, Spring Health Solution Ltd, Roche, Animas Corporation, Ypsomed AG and Insulet Corporation


To order this report: Continuous Glucose Monitoring Market (CGM Systems, Application, Diabetic Type, and Adoption by Age Group) - Current Trends, Size, Share, Industry Analysis, Competitive Intelligence, Growth, Opportunities and Global Forecasts, 2012 - 2020
http://www.reportlinker.com/p02014011/Continuous-Glucose-Monitoring-Market-CGM-Systems-Application-Diabetic-Type-and-Adoption-by-Age-Group---Current-Trends-Size-Share-Industry-Analysis-Competitive-Intelligence-Growth-Opportunities-and-Global-Forecasts-2012---2020.html



__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker